JP2025525989A5 - - Google Patents

Info

Publication number
JP2025525989A5
JP2025525989A5 JP2025507000A JP2025507000A JP2025525989A5 JP 2025525989 A5 JP2025525989 A5 JP 2025525989A5 JP 2025507000 A JP2025507000 A JP 2025507000A JP 2025507000 A JP2025507000 A JP 2025507000A JP 2025525989 A5 JP2025525989 A5 JP 2025525989A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ngf
seq
use according
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025507000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025525989A (ja
Filing date
Publication date
Priority claimed from EP22188990.0A external-priority patent/EP4316505A1/en
Application filed filed Critical
Publication of JP2025525989A publication Critical patent/JP2025525989A/ja
Publication of JP2025525989A5 publication Critical patent/JP2025525989A5/ja
Pending legal-status Critical Current

Links

JP2025507000A 2022-08-05 2023-08-04 感音性難聴の治療のためのngfの鼻腔内投与 Pending JP2025525989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22188990.0 2022-08-05
EP22188990.0A EP4316505A1 (en) 2022-08-05 2022-08-05 Intranasal administration of ngf for the treatment of sensorineural hearing loss
PCT/EP2023/071698 WO2024028487A1 (en) 2022-08-05 2023-08-04 Intranasal administration of ngf for the treatment of sensorineural hearing loss

Publications (2)

Publication Number Publication Date
JP2025525989A JP2025525989A (ja) 2025-08-07
JP2025525989A5 true JP2025525989A5 (https=) 2026-04-20

Family

ID=82846594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025507000A Pending JP2025525989A (ja) 2022-08-05 2023-08-04 感音性難聴の治療のためのngfの鼻腔内投与

Country Status (7)

Country Link
EP (2) EP4316505A1 (https=)
JP (1) JP2025525989A (https=)
CN (1) CN119836297A (https=)
AU (1) AU2023317864A1 (https=)
CA (1) CA3263975A1 (https=)
IL (1) IL318657A (https=)
WO (1) WO2024028487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4659759A1 (en) * 2024-06-04 2025-12-10 Dompé farmaceutici SpA Administration of ngf for the treatment of niemann-pick type c disease
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
ITRM20110390A1 (it) * 2011-07-21 2013-01-22 Eramo Alessandra D Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione.
EP2907521B1 (en) 2011-12-19 2017-11-22 Wacker Chemie AG Novel prongf mutants and uses thereof in the production of beta-ngf
WO2017120465A1 (en) * 2016-01-06 2017-07-13 Massachusetts Eye And Ear Infirmary Treating cochlear synaptopathy
US20190374606A1 (en) * 2017-01-27 2019-12-12 Otonomy, Inc. Neurotrophin mutants for treating hearing loss and other otic disorders
EP3406259A1 (en) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
US12378293B2 (en) 2018-04-27 2025-08-05 Chiesi Farmaceutici Spa Production of nerve growth factor (NGF) and of muteins thereof
TW202229322A (zh) * 2020-11-19 2022-08-01 大陸商舒泰神(北京)生物製藥股份有限公司 長效神經生長因數多肽及其用途

Similar Documents

Publication Publication Date Title
JP2025525989A5 (https=)
US20200384074A1 (en) Therapeutic agent for inflammatory bowel disease
JP2024503265A5 (https=)
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
JP2023500032A5 (https=)
CN109952103A (zh) 用于治疗细菌感染的系统和方法
CN109996554B (zh) 新型抗微生物和抗癌疗法
JP2025525990A5 (https=)
CA3101006A1 (fr) Diltiazem pour son utilisation dans le traitement des infections microbiennes
JP2023520703A5 (https=)
KR20230047396A (ko) 리라글루티드 및 제피티닙의 항바이러스 용도
JP2025532676A5 (https=)
ES2358018T3 (es) Uso de compuestos de kahalalida para la fabricación de un medicamento para el tratamiento de la psoriasis.
RU2025104922A (ru) Интраназальное введение ngf для лечения сенсоневральной тугоухости
US7132453B2 (en) Method of using prostacyclin to treat respiratory syncytial virus infections
CN115916185B (zh) 用于治疗腹泻的制剂和方法
JP4541642B2 (ja) 肺感染症および肺腫瘍を治療するためのリポペプチド類およびリポプロテイン類の使用
RU2025104605A (ru) Интраназальное введение нфгм для лечения сенсоневральной тугоухости
CN1098687C (zh) 氨基嘌呤抗病毒剂在治疗和预防潜伏性疱疹病毒感染中的用途
JP4846598B2 (ja) 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤
JP2024520788A5 (https=)
JP2022176154A5 (https=)
US20030073625A1 (en) Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides
US20240342227A1 (en) Combination of e. faecalis and an anti-inflammatory agent and uses thereof in the prevention and/or treatment of respiratory diseases
US20240116996A1 (en) Methods and compositions for treating a coronavirus infection